Drugs that contain Celecoxib
1. Celebrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5466823 | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
Nov, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563165 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Nov, 2013
(10 years ago) | |
|
US5563165 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
May, 2014
(9 years ago) | |
|
US5466823 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides |
May, 2014
(9 years ago) | |
| USRE44048 | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Jun, 2015
(8 years ago) | |
| US5760068 | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Jun, 2015
(8 years ago) | |
|
US5760068 (Pediatric) | UPJOHN | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Dec, 2015
(8 years ago) | |
|
USRE44048 (Pediatric) | UPJOHN | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
Dec, 2015
(8 years ago) | |
Market Authorisation Date: 15 December, 2006
Treatment: Treatment of rheumatoid arthritis; Treatment of inflammation or an inflammation-associated disorder
Dosage: CAPSULE;ORAL
How can I launch a generic of CELEBREX before it's drug patent expiration?
More Information on Dosage
CELEBREX family patents
2. Elyxyb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949990 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US10376527 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US10799517 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US9572819 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US10722456 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| US9795620 | SCILEX HLDG | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2023 |
Market Authorisation Date: 05 May, 2020
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
More Information on Dosage
ELYXYB family patents